Daily Stock Analysis, ABEO, Abeona Therapeutics Inc, priceseries

Abeona Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
15.90
Close
14.95
High
15.90
Low
14.60
Previous Close
16.20
Daily Price Gain
-1.25
YTD High
17.90
YTD High Date
Sep 18, 2017
YTD Low
4.50
YTD Low Date
Feb 1, 2017
YTD Price Change
9.95
YTD Gain
199.00%
52 Week High
17.90
52 Week High Date
Sep 18, 2017
52 Week Low
4.05
52 Week Low Date
Dec 21, 2016
52 Week Price Change
8.66
52 Week Gain
137.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 13. 2015
3.35
Apr 15. 2015
4.00
2 Trading Days
19.25%
Link
LONG
May 5. 2015
5.97
May 28. 2015
8.69
16 Trading Days
45.64%
Link
LONG
Mar 3. 2016
2.35
Mar 23. 2016
2.72
14 Trading Days
15.63%
Link
LONG
May 20. 2016
2.49
Jun 13. 2016
2.98
15 Trading Days
19.66%
Link
LONG
Jul 28. 2016
2.56
Aug 30. 2016
4.06
23 Trading Days
58.53%
Link
LONG
Sep 1. 2016
4.29
Sep 27. 2016
5.61
17 Trading Days
30.86%
Link
LONG
Jan 3. 2017
5.00
Jan 11. 2017
5.27
6 Trading Days
5.46%
Link
LONG
Apr 19. 2017
5.05
May 3. 2017
5.31
10 Trading Days
5.24%
Link
LONG
Jun 21. 2017
5.00
Jul 25. 2017
8.91
23 Trading Days
78.11%
Link
LONG
Aug 23. 2017
8.75
Sep 22. 2017
14.99
22 Trading Days
71.29%
Link
Company Information
Stock Symbol
ABEO
Exchange
NasdaqCM
Company URL
http://www.abeonatherapeutics.com
Company Phone
2149055100
CEO
Timothy J. Miller
Headquarters
Texas
Business Address
3333 LEE PARKWAY, SUITE 600, DALLAS, TX 75219
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000318306
About

Abeona Therapeutics, Inc. operates as an emerging pharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. It focuses on developing a range of pharmaceutical and medical device products primarily based upon nanopolymer chemistry technologies and other drug delivery technologies. The company's products are ProctiGard, LexaGard, CobOral and CobaCyte. Abeona Therapeutics was founded in 1974 and is headquartered in Dallas, TX.

Description

Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.